Cas:90657-53-7 (2S,4S)-4-Phenylpyrrolidine-2-carboxylic acid hydrochloride manufacturer & supplier

Chemical Name:(2S,4S)-4-Phenylpyrrolidine-2-carboxylic acid hydrochloride

CAS.NO:90657-53-7

Synonyms:(2S,4S)-4-phenylpyrrolidine-2-carboxylic acid,hydrochloride;MFCD08061932;(4S)-4-Phenyl-L-proline hydrochloride (1:1);L-Proline, 4-phenyl-, (4S)-, hydrochloride (1:1)

Molecular Formula:C₁₁H₁₄ClNO₂

Molecular Weight:227.687

HS Code:

Physical and Chemical Properties:

Melting point:134-140ºC

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:49.33000

Exact Mass:227.071304

LogP:2.34750

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (2S,4S)-4-phenylpyrrolidine-2-carboxylic acid,hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,L-Proline, 4-phenyl-, (4S)-, hydrochloride (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2S,4S)-4-phenylpyrrolidine-2-carboxylic acid,hydrochloride Use and application,(4S)-4-Phenyl-L-proline hydrochloride (1:1) technical grade,usp/ep/jp grade.

Related News: The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented. (2S,4S)-4-Phenylpyrrolidine-2-carboxylic acid hydrochloride manufacturer The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. (2S,4S)-4-Phenylpyrrolidine-2-carboxylic acid hydrochloride supplier In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. (2S,4S)-4-Phenylpyrrolidine-2-carboxylic acid hydrochloride vendor Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037. (2S,4S)-4-Phenylpyrrolidine-2-carboxylic acid hydrochloride factory Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase.